STEP-HFpEF Trials: Efficacy of Semaglutide by Sex in Obesity-Related HFpEF | ADA 2024

Harlan Krumholz, MD, FACC, Editor-in-Chief of JACC and Subodh Verma, MD, PhD discuss a pre-specified sub-analysis from the STEP-HF program, involving two trials on obesity-related heart failure with preserved ejection fraction, including 1,145 subjects. This analysis focused on sex differences, revealing that women lose more weight with semaglutide yet experience the same cardiovascular benefits as men, indicating the drug's disease-modifying effects beyond weight loss. Baseline characteristics showed that women with this condition have higher symptom burdens, more inflammation, and higher BMI compared to men, challenging previous perceptions and highlighting the need for targeted treatment strategies. These findings emphasize the importance of addressing sex-specific differences in managing heart failure with preserved ejection fraction.
Expert analysis and key takeaways:
Introduction (00:00)
STEP-HF Program background (00:31)
Rationale for looking at sex differences (02:58)
Semaglutide/benefits/diabetes (03:27)
Baseline characteristics in male vs. female obesity related HFpEF (04:35)
Important takeaways (06:47)
Related article:
www.jacc.org/doi/10.1016/j.ja...
#jacc #jaccjournals adascisessions